JP2003531157A5 - - Google Patents

Download PDF

Info

Publication number
JP2003531157A5
JP2003531157A5 JP2001577898A JP2001577898A JP2003531157A5 JP 2003531157 A5 JP2003531157 A5 JP 2003531157A5 JP 2001577898 A JP2001577898 A JP 2001577898A JP 2001577898 A JP2001577898 A JP 2001577898A JP 2003531157 A5 JP2003531157 A5 JP 2003531157A5
Authority
JP
Japan
Prior art keywords
present
pharmacology
medicine
fields
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001577898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/013135 external-priority patent/WO2001080796A1/en
Publication of JP2003531157A publication Critical patent/JP2003531157A/ja
Publication of JP2003531157A5 publication Critical patent/JP2003531157A5/ja
Pending legal-status Critical Current

Links

JP2001577898A 2000-04-26 2001-04-24 オキシブチニン治療に関連した有害な経験の最小化 Pending JP2003531157A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55971100A 2000-04-26 2000-04-26
US09/559,711 2000-04-26
PCT/US2001/013135 WO2001080796A1 (en) 2000-04-26 2001-04-24 Minimizing adverse experience associated with oxybutynin therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012272243A Division JP6077294B2 (ja) 2000-04-26 2012-12-13 オキシブチニン治療に関連した有害な経験の最小化

Publications (2)

Publication Number Publication Date
JP2003531157A JP2003531157A (ja) 2003-10-21
JP2003531157A5 true JP2003531157A5 (https=) 2012-02-23

Family

ID=24234699

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001577898A Pending JP2003531157A (ja) 2000-04-26 2001-04-24 オキシブチニン治療に関連した有害な経験の最小化
JP2012272243A Expired - Lifetime JP6077294B2 (ja) 2000-04-26 2012-12-13 オキシブチニン治療に関連した有害な経験の最小化
JP2016160805A Expired - Lifetime JP6253734B2 (ja) 2000-04-26 2016-08-18 オキシブチニン治療に関連した有害な経験の最小化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012272243A Expired - Lifetime JP6077294B2 (ja) 2000-04-26 2012-12-13 オキシブチニン治療に関連した有害な経験の最小化
JP2016160805A Expired - Lifetime JP6253734B2 (ja) 2000-04-26 2016-08-18 オキシブチニン治療に関連した有害な経験の最小化

Country Status (15)

Country Link
US (6) US6743441B2 (https=)
EP (3) EP1992342A1 (https=)
JP (3) JP2003531157A (https=)
CN (4) CN1438861A (https=)
AT (1) ATE488233T1 (https=)
AU (2) AU5378201A (https=)
BR (1) BR0110381A (https=)
CA (1) CA2406064C (https=)
CY (1) CY1111498T1 (https=)
DE (1) DE60143477D1 (https=)
DK (1) DK1280486T3 (https=)
ES (1) ES2357699T3 (https=)
MX (2) MX342305B (https=)
PT (1) PT1280486E (https=)
WO (1) WO2001080796A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
JP2003531157A (ja) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US7276068B2 (en) 2002-10-04 2007-10-02 Sherwood Services Ag Vessel sealing instrument with electrical cutting mechanism
AU2012216593B2 (en) * 2002-11-01 2014-09-25 Allergan Sales, Llc Compositions and methods for transdermal oxybutynin therapy
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
MXPA05007266A (es) * 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
JP5097359B2 (ja) 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP4122460A1 (en) 2015-01-09 2023-01-25 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
EP4729123A2 (en) 2017-04-24 2026-04-22 Alto Neuroscience, Inc. Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
JP6748237B2 (ja) * 2017-08-01 2020-08-26 久光製薬株式会社 貼付剤
AU2024233006A1 (en) * 2023-03-03 2025-08-28 Lotus Biopharma Inc. Microsphere formulations and methods of preparation thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147236A (en) * 1874-02-10 Improvement in devices for riveting the teeth of saws
NL267508A (https=) * 1960-07-26
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5028430A (en) 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
DE69029804T2 (de) * 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
US5922342A (en) 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
DE69326848T2 (de) * 1992-05-13 2000-01-27 Alza Corp Oxybutynin zur transdermalen Verabreichung
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
CA2165802A1 (en) 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
ATE246909T1 (de) 1994-03-07 2003-08-15 Theratech Inc Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung
US5441740A (en) * 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
KR100209469B1 (ko) * 1994-10-05 1999-07-15 나까도미 히로다카 N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형 제제
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5582838A (en) 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5862555A (en) 1995-04-06 1999-01-26 Furuhashi; Masanobu System and method for manufacturing shoes using a wooden mold
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
ES2233768T3 (es) 1996-02-02 2005-06-16 Alza Corporation Liberacion prolongada de un agente activo utilizando un sistema implantable.
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5769683A (en) * 1997-02-10 1998-06-23 Park; Young-Ho Attachment for balloon tether
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6479373B2 (en) * 1997-02-20 2002-11-12 Infineon Technologies Ag Method of structuring layers with a polysilicon layer and an overlying metal or metal silicide layer using a three step etching process with fluorine, chlorine, bromine containing gases
IL132040A (en) 1997-03-31 2004-07-25 Alza Corp Prolonged release transfer system and method
EP0971641A4 (en) 1997-04-03 2003-08-13 Point Biomedical Corp SYSTEM FOR THE ADMINISTRATION OF AN INTRAVESICAL MEDICINAL PRODUCT
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6319913B1 (en) * 1997-11-10 2001-11-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US5891888A (en) * 1998-01-14 1999-04-06 Strahl; Robert Charles Physical endurance drink
DE19812413C1 (de) * 1998-03-20 1999-06-10 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
AR018321A1 (es) 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US5986305A (en) * 1998-03-30 1999-11-16 Texas Instruments - Acer Incorporated Semiconductor device with an inverse-T gate lightly-doped drain structure
FR2779438B1 (fr) * 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
JP2003531157A (ja) 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US6682368B2 (en) * 2000-05-31 2004-01-27 Tyco Electronics Corporation Electrical connector assembly utilizing multiple ground planes
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6662368B1 (en) * 2000-09-11 2003-12-09 Arris International, Inc. Variable spare circuit group size and quantity having multiple active circuits

Similar Documents

Publication Publication Date Title
JP2003531157A5 (https=)
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
SE0104340D0 (sv) New compounds
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
MXPA03011972A (es) Arilaminas para tratamiento de condiciones asociadas con gsk-3.
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
NO20053920D0 (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DK1244435T3 (da) Polyhydroxylerede, aromatiske forbindelser til behandling af amyloidose og alpha-synuclein fibril sygdomme
JP2003520232A5 (https=)
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
JP2005237328A5 (https=)
SE0201544D0 (sv) Novel compounds and thier use
JP2005504782A5 (https=)
JP2005509503A5 (https=)
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
SE0003476D0 (sv) Compounds
JP2004505922A5 (https=)
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet